Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$3.29 +0.2%	$3.93	$2.76 ▼ $13.50	$184.98M	N/A	428,629 shs	444,413 shs
ARVN Arvinas	$7.89 -0.1%	$7.30	$5.90 ▼ $34.11	$580.28M	2.17	1.46 million shs	826,658 shs
EVO Evotec	$4.20 -3.3%	$4.14	$2.84 ▼ $5.64	$1.49B	1.66	135,916 shs	61,993 shs
RXRX Recursion Pharmaceuticals	$5.26 +1.0%	$4.85	$3.79 ▼ $12.36	$2.14B	0.91	15.97 million shs	16.58 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+0.15%	-0.45%	-4.78%	-67.31%	+328,499,900.00%
ARVN Arvinas	-0.11%	+1.17%	+12.73%	+20.29%	-66.98%
EVO Evotec	-3.34%	-0.59%	+4.09%	+37.09%	-18.54%
RXRX Recursion Pharmaceuticals	+0.96%	-2.59%	+19.82%	+24.06%	-28.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALMS Alumis	3.1143 of 5 stars	3.6	0.0	1.1	3.3	1.3
ARVN Arvinas	3.1265 of 5 stars	4.3	2.0	0.0	2.5	1.3
EVO Evotec	1.7221 of 5 stars	3.2	2.0	2.3	0.0	0.6
RXRX Recursion Pharmaceuticals	2.1072 of 5 stars	3.2	1.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	3.22	Buy	$22.86	595.80% Upside
ARVN Arvinas	2.55	Moderate Buy	$20.29	157.12% Upside
EVO Evotec	2.40	Hold	$5.93	41.44% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	33.08% Upside

Current Analyst Ratings Breakdown

Latest ALMS, ARVN, EVO, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/10/2025	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$18.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	EVO Evotec	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/15/2025	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $25.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/9/2025	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	N/A	N/A	N/A	N/A	$5.51 per share	N/A
ARVN Arvinas	$263.40M	2.19	N/A	N/A	$8.17 per share	0.97
EVO Evotec	$862.40M	1.73	N/A	N/A	$2.91 per share	1.44
RXRX Recursion Pharmaceuticals	$58.84M	36.34	N/A	N/A	$2.61 per share	2.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$294.23M	N/A	0.00	N/A	N/A	N/A	-406.27%	-107.29%	8/12/2025 (Estimated)
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-26.34%	-21.51%	-10.54%	8/13/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest ALMS, ARVN, EVO, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
5/14/2025	Q1 2025	ALMS Alumis	-$1.47	-$1.82	-$0.35	-$1.82	N/A	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	3.73	3.73
ARVN Arvinas	N/A	4.58	4.58
EVO Evotec	0.46	2.03	1.93
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
ARVN Arvinas	95.19%
EVO Evotec	5.81%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	40.70%
ARVN Arvinas	4.73%
EVO Evotec	1.00%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	54.41 million	32.26 million	N/A
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
EVO Evotec	4,827	355.11 million	351.56 million	Not Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

ALMS, ARVN, EVO, and RXRX Headlines

Recent News About These Companies

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

July 3 at 6:51 PM | zacks.com

What Analysts Are Saying About Recursion Pharmaceuticals Stock

July 3 at 5:45 PM | benzinga.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Earns Equal Weight Rating from Analysts at Morgan Stanley

July 3 at 8:46 AM | marketbeat.com

Kinnevik AB publ Has $71.07 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 3 at 8:17 AM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 3.2% - Time to Buy?

July 2 at 1:37 PM | marketbeat.com

Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?

July 2 at 11:30 AM | zacks.com

Sumitomo Mitsui Trust Group Inc. Has $44.86 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 2 at 4:33 AM | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX) - Yahoo Finance

July 1 at 11:14 AM | finance.yahoo.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.5% - Should You Buy?

June 30, 2025 | marketbeat.com

MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy

June 30, 2025 | msn.com

Recursion Pharmaceuticals Inc Class A RXRX - Morningstar

June 28, 2025 | morningstar.comM

Why This Wildcard Stock Could Be a Future Star

June 28, 2025 | msn.com

Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note

June 27, 2025 | zacks.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.2% - Time to Sell?

June 26, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's What Happened

June 26, 2025 | marketbeat.com

Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating

June 26, 2025 | msn.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.9% - What's Next?

June 25, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 7.3% - Time to Buy?

June 24, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts

June 24, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?

June 23, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

June 20, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop
Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype?
By Leo Miller | June 20, 2025
View Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype?
Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later?
By Jeffrey Neal Johnson | June 6, 2025
View Is Affirm Stock Buy Now, Profit Later or Buy Now, Pay Later?
QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally
By Leo Miller | June 27, 2025
View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally

ALMS, ARVN, EVO, and RXRX Company Descriptions

Alumis NASDAQ:ALMS

$3.28 +0.01 (+0.15%)

Closing price 07/3/2025 03:09 PM Eastern

Extended Trading

$3.36 +0.07 (+2.28%)

As of 07/3/2025 04:49 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)

Closing price 07/3/2025 02:37 PM Eastern

Extended Trading

$7.96 +0.07 (+0.87%)

As of 07/3/2025 04:59 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Evotec NASDAQ:EVO

$4.20 -0.15 (-3.34%)

As of 07/3/2025 01:52 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.26 +0.05 (+0.96%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$5.24 -0.01 (-0.29%)

As of 07/3/2025 04:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time